PhRMA takes shot at payers in drug pricing war

A new print and digital ad campaign dubbed "Share the Savings" suggests insurers aren't passing along the discounts they receive from drugmakers. 

By Ned Pagliarulo • April 6, 2017

Sanofi pays $20M bill to resolve claims of overcharging

The French pharma's vaccines arm will shell out to resolve claims it overcharged the VA between 2002 and 2011.

By Suzanne Elvidge • April 5, 2017

Explore the Trendline➔

Commercialization

New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

By BioPharma Dive staff

Should the US government license hep C drugs?

The National Academies of Sciences, Engineering and Medicine is looking at innovative payment models to address ways to treat all patients with hepatitis C, while not depriving pharmaceutical companies of sales. 

By Suzanne Elvidge • March 31, 2017

Drug prices continue to climb, but who's to blame?

A new report released by the powerful industry trade group PhRMA says payers are failing to pass on savings to consumers from drugmaker discounts. 

By Ned Pagliarulo , Suzanne Elvidge • March 30, 2017

Legwork leaves Sanofi, Regeneron confident in Dupixent uptake

The companies are optimistic about the prospects of their eczema drug Dupixent, which has a list price of $37,000 per year, getting on payer formularies. 

By Jacob Bell • March 29, 2017

Sanofi, Regeneron's eczema drug Dupixent gains FDA approval

The highly-anticipated Dupixent is expected to rake in around $3 billion in peak annual sales, according to some industry followers.

By Jacob Bell • March 28, 2017

JAMA confirms DTC drove 'Low-T' craze

A recent report shows the strength of DTC advertising and how it can be abused. 

By Lisa LaMotta • March 23, 2017

J&J, GSK pull ads from YouTube amid display concerns

A growing list of major corporations have paused advertising on the media channel due to alarm that product marketing may be appearing next to offensive material. 

By Ned Pagliarulo • March 23, 2017

Newron finally secures US approval for Parkinson's drug

Xadago has been approved in the EU since early 2015, but troubles with the FDA had kept it off the U.S. market until now. 

By Suzanne Elvidge • March 22, 2017

Lilly offers up drug pricing details amid ongoing scrutiny of industry

Following criticism over the cost of its insulin drugs, the company gave a glimpse into its pricing decisions in an annual report.

By Jacob Bell • March 20, 2017

FDA advisory panel votes against Endo's opioid painkiller

After the panel concluded the risks associated with Opana ER outweigh its benefits, the FDA will now have to decide what reforms to take for the prescription opioid.

By Jacob Bell • March 15, 2017

OncBioMune, EOC aim to develop gastric cancer drug

The commercialization deal is part of the Louisiana-based biopharma’s push southward into Mexico, Central America and South America.

By Judy Packer-Tursman • March 15, 2017

Bernie Sanders calls for more broadcast news on drug pricing

The Vermont senator sent a letter to Fox News, CNN and four other television news networks criticizing their lack of coverage on pharmaceutical pricing.

By Jacob Bell • March 15, 2017

Acorda taps Amazon's Alexa to build MS awareness

Say "Alexa, start MS Awareness," and Amazon's voice recognition software will deliver facts and tips about multiple sclerosis from Acorda's app. 

By Suzanne Elvidge • March 15, 2017

Mylan clears way for biosimilar Herceptin launch in US

The EpiPen manufacturer reached a settlement deal with Roche, granting Mylan a license to commercialize what could be the first Herceptin copy in the U.S. 

By Ned Pagliarulo • March 13, 2017

Using social to tap into the rare disease market

The annual Rare Disease Day is designed to connect the rare disease community, build awareness and raise research funds.

By Judy Packer-Tursman • March 10, 2017

5 biotech CEOs on payers, investors and big bets

BioPharma Dive sat down with the top executives from several biotechs at the BIO CEO conference in New York. Here is what they had to say about the challenges they face, dealing with payers and educating investors. 

By Lisa LaMotta • March 9, 2017

Express Scripts challenges Gilead in pricing blame game

The pharmacy benefit manager fired back at Gilead, calling on the drugmaker to lower the costs of its hepatitis C medicines and reimburse payers. 

By Lisa LaMotta • March 8, 2017

MS drugs too expensive, ICER says

A new report from the Institute for Clinical and Economic Review found only Sanofi's Lemtrada met its cost-effectiveness benchmark. 

By Ned Pagliarulo • March 7, 2017

Amgen debuts Repatha ad amid ongoing patent battle

The 1-minute clip touts the PCSK9 drug's potential as a better cholesterol-lowering option than statin monotherapy.

By Jacob Bell • March 7, 2017

Pressure builds on Marathon over orphan drug price

A group of senators sent a letter asking for answers from the drugmaker on how it decided to price its newly approved DMD treatment at $89,000 per year. 

By Ned Pagliarulo • March 7, 2017

FDA gives go-ahead to Lexicon's rare disease drug

The company plans to price Xermelo, a drug for carcinoid syndrome diarrhea, similarly to Novartis' leading treatment for the condition.

By Jacob Bell • March 1, 2017

Napo amps up sales force for AIDS anti-diarrheal

The San Francisco-based company, which has inked a deal for a shared sales and sampling program, expects Mytesi to generate about $7 million in sales this year.

By Judy Packer-Tursman • March 1, 2017

How DTC got things moving for Linzess

The biotech has transitioned through three iterations of its DTC campaign for Linzess in as many years, despite each one being successful. 

By Lisa LaMotta • March 1, 2017

Allergan eyes up dry eye patients

"Before we had our voice, we had our eyes," reminds the Eyepowerment campaign created to empower patients to look more closely at their dry eyes. 

By Suzanne Elvidge • March 1, 2017